IRICoR contributes to a major discovery on the mechanism of drug resistance in leukemia and other cancers

Understanding and overcoming a novel type of anticancer drug resistance

A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Katherine Borden of the University of Montreal’s Institute for Research in Immunology and Cancer (IRIC) and her collaborators. Katherine Borden is a Principal Investigator at IRIC and a professor at the university’s Department of Pathology and Cell Biology. The development of drug resistance is one of the main problems in clinical oncology and the cause of relapse in many patients.  Continue reading

© 2008-2020 IRICoR